|Grant Affiliation:||Farzan: Preventing HIV-1 transmission with a novel entry inhibitor, eCD4-Ig|
|Strategy:||Prophylactic neutralizing Ab|
|Study Type:||Antibody Screening|
|Study Start Date:||NA|
|Study Made Public:||NA|
CAVD 812 is an immunogenicity study evaluating eCD4-Ig variants.
Sign in to see full information about this study and to download study data.
ProductsNo Products used in study
No integrated data is available for this study.